NOVAVAX in an Ascending breakout. Potential upside of 30%NOVAVAX close to a breakout point. Risk reward 2:1.
NVAX
$NVAX - Gap up playGM traders! Hope you had a nice Memorial Day Weekend.
$NVAX gapping up +20% this morning, covid-19 vaccine play, phase 1 clinical trial news.
2 ways to play this:
1. look to short at premarket high and top of resistance area before the daily gap up, anywhere between 58.62 (PM high) and 61.50, target price is premarket low around 53 area. Risk 1: Reward 6
2. look to go long after breaking resistance area, and pull back. +80% gap fill within 2 days, enter near 60 area and target 80. Risk 3: Reward 20
Novavax Technical and Fundamental AnalysisTechnical Analysis - Check/wait if one of the supports will not be broken before buying
On a daily chart there might be a Bottom Saucer or Rounding Reversal Pattern
Fundamental News:
Novavax (NASDAQ:NVAX) is a clinical-stage biotechnology company focused on the discovery, development and commercialisation of vaccines and adjuvants. Through its recombinant nanoparticle vaccine technology, it produces vaccine candidates to respond to both known and newly emerging diseases.
Novavax topped Wall Street expectations for the first quarter when it reported a loss of 58 cents per share on revenue of $3.4 million earlier this month. Analysts were expecting a loss of 69 cents per share and revenue of $1.9 million.
More importantly, the biotech company announced in its earnings release that the Oslo-based nonprofit Coalition for Epidemic Preparedness Innovations will invest $384 million to advance the clinical development of its SARS-CoV-2 vaccine candidate, NVX-CoV2373.
Novavax plans to start human trials in May with preliminary results expected in July.
[NVAX] Sliding Back to $40, Collapse if It Breaks ThroughI missed this guy when I jumped on MRNA and INO earlier this week.
Just trying to pin this one down a bit, coronavirus stocks are wild and fun :).
For FOMO stocks, typical support and resistance horizontal lines aren't as predictive and you should instead look to the Volume Profile.
Support should be right around the POC, which is $40.
It should slide down to that and hang a bit before breaking through and crashing down. May bounce back up too but seems unlikely.
All indicators are lining up at the start of a downward channel and signaling a short move too.
June market crash is probably gonna move this more than anything as retail tries to secure their tiny profits or stem their massive losses.
VBIV day trade [Price Target: $1.60]IFFFFF the $1.98 - $2.00 support line holds and buying pressure increases, I expect to see a pretty big upward price movement for the day. Remember folks, just ideas!
Vaccine candidates seeing huge gains.A good trade to consider is vaccine development companies. Some of the major players are Novavax, Moderna and Giliad. A conservative price target might be 15-25%.
Novavax (NVAX): Tell me about my Schiff!I'm bull-ish on Novavax (see Related Idea). I think their approach to the COVID-19 vaccine is promising - their recombinant nanoparticle vaccine technology and Matrix-M adjuvant. They also have positive long-term prospects with their proprietary NanoFlu candidate. This is the big one to me. It's unclear whether COVID-19 becomes seasonal or not but influenza is established and recurring. It fact, it's becoming more difficult to handle with every year. The strains are becoming more advanced and unpredictable. Whether or not Novavax can produce a profitable candidate, I simply don't know. I believe that their patented tech is promising.
Novavax might not produce a COVID vaccine before its competitors (or at all) but they continue to demonstrate their technology and approach works. Example: ir.novavax.com
That being said, tell me about this random Schiff I plotted :)
Matrix-M Adjuvant: novavax.com
NanoFlu Phase 3 topline data: novavax.com
RSV F Vaccine: novavax.com
Gild Bullish trend-line PlayGilead Sciences , Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Entry $77.50 area
Target $2 trailing stoploss
I been trading this stock for over a year now and once it form it's base, it usually hold itself very well in it's pattern.
we could've easily scalped this stock multiple time this month for easy gain if you just buy the dip at the trend line with a tight stoploss.
NVAX great swing into earnings. Go long, tight stop. NASDAQ:NVAX is giving us a great swing trade setup. few days to print. VWAP, fast MA, med MA sitting above slow MA for a long time and offering up a beautiful retracement that will bounce off the indicators right before earnings. Go long, and set a stop where VWAP gets crossed down by the fast MA AND the med MA. Should bring a 4:1 profit to risk ratio.
Bullish Pennant on novavax 30 min chartLooks like Novavax is consolidating for a strong move upward. NASDAQ:NVAX
$NVAX Play The Break Out Above $18$NVAX is setting up as nice day trade if we get above $18 and the 52 week high of $18.25 a share. We could see $20 a share pretty easy, especially with the news out today.
MELBOURNE, Australia, April 16, 2020 /PRNewswire/ -- As part of the urgent global race to develop a vaccine to tackle the Coronavirus COVID-19 outbreak, Nucleus is due to commence Phase 1 testing for the Novavax SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, NVX-CoV2373, at its Melbourne and Brisbane clinics within the coming weeks.
"Nucleus has a rich history of Phase 1 vaccine trials, and a long-standing track-record with Novavax (NVAX)," says Nucleus CEO Cameron Johnson. "This is the third confirmed global COVID19 vaccine trial and the first in Australia and we are well positioned to implement rapid testing with first-in-human trials over the coming weeks.
"With the capacity to conduct this trial across both our Melbourne and Brisbane clinics, we will be assisting Novavax to undertake Phase 1 trials and fast track NVX-CoV2373 to potential subsequent development as soon as possible," adds Johnson.
Novavax's early development efforts on vaccines for two other recent coronavirus epidemics – severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), along with prior work on Ebola (phase 1 trial conducted in Australia) – allows them to leverage their understanding of coronaviruses and adapt their research to create a vaccine for SARS-CoV-2, the virus that causes COVID-19.
"The urgent global race to develop a vaccine against the COVID-19 pandemic drove our rapid identification and selection of an optimal, highly immunogenic vaccine candidate," said Stanley C. Erck, President and CEO of Novavax. "We are pleased that Nucleus, our long-time partner, was able to accommodate our accelerated timeline."
The Phase 1 trial of NVX-CoV2373 is expected to begin in mid-May with preliminary immunogenicity and safety results in July.
The scale and absolute commitment to the highest standards make Nucleus the ideal partner in the rapid development of the vaccine for COVID-19.
"We own 150 of the total 250 dedicated phase I beds available in Australia over two sites in Melbourne and Brisbane, located within major medical precincts. Supported by our workforce of over 400 specialists, we are in the unique position of offering sponsors a multi-site pathway to conduct their clinical trials," says Johnson.
This scale allows Nucleus to address the urgency of the COVID-19 vaccine studies, without interruption to other ongoing clinical trials. The standards ensure the reliability of the studies, especially in the current pandemic situation across the world.
"For all of our clinical trials, Nucleus has implemented the highest level of Transmission-Based Precautions within its clinical units including the creation of dedicated teams of clinical staff," says Nucleus Infectious Diseases Physician and Microbiologist and, Associate Professor of Medicine at the University of Queensland, Dr Paul Griffin. "These staff are assigned to work only in functional designated areas and there is no cross-pollination of these teams, improving safety, reducing study risk, and ensuring integrity of the trials."
As a key partner in the development of these promising vaccine candidates, Nucleus' role in solving the current pandemic is top of mind for Johnson.
"As COVID-19 continues to impact the everyday life of all global citizens, finding a solution has become an urgent objective for governments and health organisations around the world. The world is watching and we're on the front line, supporting Novavax to unlock the potential of a Coronavirus COVID-19 vaccine."
Good luck to all!
Novavax $NVAX#Novavax hit the weekly 100SMA and stalling and forming double top. It may pull back on next week.
Daytrading RECAP 04/08/20 - 3 Longs & 1 Short for +1.6%!Hi traders,
Tom with another recap here.
*In my ID trades, I risk 1% of the account per trade and go for 2% (2:1 RRR ). Sometimes I adapt a little bit as you can see in the description.*
I switched to video recaps so you can see the charts in greater detail. Let me know if you like it!
Four trades today:
1) UPS - LONG @95.04, stopped out at 94.27 for a little under -1%
2) T - SHORT @29.62, closed half at 2:1 and the rest at B/E (messed that up). Total profit a bit over +1%
3) NVAX - LONG @16.75, closed half at 2:1 and let the rest run some more, closed just before 18 for a total of +2.5%!
4) PINS - LONG @16.9, the stock couldn't hold the pressure and collapsed into my SL @16.4 for -1%
Total PnL for the day: +1.6%
Total PnL for the week: +2.05%
In hindsight, I left money on the table with T and should've reversed PINS after it stopped me out and showed big pressure to the downside.
Mistakes are great teachers for your trading, learn to accept them and work with them!
Good trades and let me know how your Wednesday trading went!
Tom from FINEIGHT
$NVAX Dances While the Music Plays, But What's Next?NVAX ramped on the squeeze as crowd psychology and algorithmic logic took hold in the market crash last week. But this company has as much chance of participating in the actual vaccine as my aunt's family chicken soup recipe. We look for the fade.
$NVAX Still Seems Like a Short in the MakingNVAX is one, of all the COVID-2019 movers, that we think is most likely to end up being a great short down the line.
The long-term trajectory speaks of numerous failures to execute in clinical development, and the company is not part of the inside clique with funding to solve the virus vaccine puzzle. But it's up almost 100% since the news first broke last month.
$NVAX Coronavirus Pop May Be Rolling Over AlreadyNVAX
The "inevitability bell" may be starting to ring on this one. We called it short a few days ago -- and 7% higher. And now we may be seeing this start to play along. If short with us here, stops should be set in place in the $8.75 area to fence off the unbounded squeeze risk.
NVAX coronavirus panic.NVAX coronavirus panic. Currently, several biotech shares rose significantly yesterday. The driving force is a fundamental fear of the coronavirus. NVAX is one of the potential candidates who can isolate and solve the problem. The fair value of NVAX stock is currently around USD 11.5. Technically, the stock price is in the right place. But what about panic? Is technology down there? ... Not sure. With braver target prices, the next upswing can be exploited. Let's start with the most basic target price rule. The target price is the sum of the closing value of the given trading time frame and the ATR of the two farthest moving averages measured at the closing values. Where can we be brave here? There to raise the timeframe to W1. In this timeframe, we generate a closing value ATR and this can give you a target price level. So if we calculate a target price using W1 ATR calculation, then the target price can be 33.6usd. A 231% increase from the current level. This analysis is highly speculative. But in panic it can easily work.
NVAX possibly start up trendNVAX possibly start up trend. wait for 123 confirmation. I also watcing this one
